Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The information provided in this blog post is for informational purposes only and is not intended as medical advice
Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides
John Myers, a Baltimore physician, developed it decades ago, and it's still where a lot of patients start
Its a targeted solution that focuses purely on arousal, offering peace of mind
Combination therapies Newer combination treatments like CagriSema (cagrilintide plus semaglutide) are being studied as weekly injections
